Drug Trial Radar · NCT01243944
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Last checked: Nov 20, 2026Latest source record: Mar 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Oct 27, 2010
Primary completion
Jan 15, 2014
Study completion Feb 9, 2018
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Nov 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
Conditions
- Polycythemia Vera
Interventions
ruxolitinib tabletsDrug
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Best Available Therapy (BAT)Other
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Percentage of Participants Achieving a Primary Response at Week 32Time frame: 32 Weeks
Locations
102 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Scottsdale, Arizona
Site not named
Pomona, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Bridgeport, Connecticut
Site not named
New Haven, Connecticut
Site not named
Boynton Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Jacksonville, Florida
Site not named
Winter Park, Florida
Site not named
Boise, Idaho
Site not named
Chicago, Illinois
Site not named
Lafayette, Louisiana
Site not named
Scarborough, Maine
Site not named
Baltimore, Maryland
Site not named
Columbia, Maryland
Site not named
Southfield, Michigan
Site not named
Jefferson City, Missouri
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Morristown, New Jersey
Site not named
Somerville, New Jersey
Site not named
Charleston, South Carolina
Site not named
Greenville, South Carolina
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Seattle, Washington
Site not named
Buenos Aires, Argentina
Site not named
Brisbane, Australia
Site not named
Parkville, Australia
Site not named
Tweed Heads, Australia
Site not named
Antwerp, Belgium
Site not named
Bruges, Belgium
Site not named
Brussels, Belgium
Site not named
Leuven, Belgium
Site not named
Hamilton, Canada
Site not named
Montreal, Canada
Site not named
Toronto, Canada
Site not named
Beijing, China
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.